论文部分内容阅读
近几十年,变应性鼻炎及哮喘的患病率急剧增高,极大地影响了患者的生活质量,并给患者和社会增加了巨大的经济负担。目前该类疾病的治疗仍以抗组胺、糖皮质激素等药物治疗为主,变应原提取蛋白特异性免疫治疗虽已得到逐渐认可和大力推广,但其疗效有时不稳定,在标准化、安全性及依从性等问题上常被质疑和诟病。为克服传统变应原疫苗的局限性,寻求一个更有效的预防和治疗变应性疾病的方法,DNA疫苗目前成为针对变应性鼻炎及哮喘的免疫治疗的疫苗研究热点,现对其在变应性鼻炎及哮喘等呼吸道变应性疾病中的研究进展做一介绍。
In recent decades, the sharp increase in the prevalence of allergic rhinitis and asthma has greatly affected the quality of life of patients and has brought tremendous financial burden on patients and society. Currently the treatment of such diseases is still dominated by antihistamines, glucocorticoid and other drug-based therapy, allergen-specific protein-specific immunotherapy has been gradually recognized and vigorously promoted, but its efficacy is sometimes unstable, standardized, safe Sexual and compliance issues are often questioned and criticized. In order to overcome the limitations of traditional allergen vaccines and to find a more effective method to prevent and treat allergic diseases, DNA vaccines are currently becoming the hotspots of vaccines for immunotherapy of allergic rhinitis and asthma. Allergic rhinitis and asthma and other respiratory allergic diseases in the progress of an introduction.